Basilea Pharmaceutica Ltd. Logo
 

Portfolio

 
 
 

Basilea focuses on the development of antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.


Pipeline Website E 20170810.xlsx

  • Isavuconazole is an intravenous (i.v.) and oral azole antifungal and the active agent of the prodrug isavuconazonium sulfate. It received marketing authorization in Europe for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.1 It is approved in the United States for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis.2

  • Ceftobiprole is a cephalosporin antibiotic for i.v. administration with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria, including methicillin-susceptible and resistant Staphylococcus aureus (MSSA, MRSA) and susceptible Pseudomonas spp. The drug is approved for sale in 13 European countries and several non-European countries for the treatment of adult patients with community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP).3

Basilea's pipeline includes two early-stage oncology drug candidates:

  • BAL101553 is a clinical stage tumor checkpoint controller being developed as a potential therapy for diverse cancers, including tumor types unresponsive to standard therapeutics. BAL101553 is currently not approved in any jurisdiction. 
  • BAL3833 is a phase 1 orally available small-molecule drug candidate. It is a panRAF/SRC kinase inhibitor as it blocks BRAF and CRAF and also inhibits the SRC kinase family. BAL3833 is currently not approved in any jurisdiction. 

 

Footnotes

1.  European Public Assessment Report (EPAR) Cresemba

2. Cresemba U.S. prescribing information

3. U.K. Summary of Product Characteristics (SPC)

 

 

 
Info